Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified
The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery.